Insulet (Nasdaq:PODD) today shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes. The maker of the Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — said during a 2025 Investor Day event that it plans to bring its first fully closed-loop system […]
Diabetes
Dexcom highlights breakthrough type 2 diabetes outcomes at ATTD
Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026. San Diego-based Dexcom plans to highlight the benefits of its continuous glucose monitor (CGM) biosensor technology for people with all types of diabetes across the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona this […]
MiniMed picks up CE mark for MiniMed 780G pump with Instinct sensor made by Abbott
MiniMed (Nasdaq:MMED) announced today that it received CE mark for the use of its MiniMed 780G with the Instinct sensor made by Abbott. Northridge, California-based MiniMed — which just went public as part of its separation from Medtronic — now offers more sensor choices for users of its most advanced automated insulin delivery system. The […]
Glooko integrates diabetes management tech with Roche CGM
Glooko announced today that it agreed to integrate its diabetes management platform with the Roche Accu-Chek SmartGuide CGM. The integration enables users of the Roche continuous glucose monitor (CGM) to bring their data into Glooko alongside data from other connected diabetes and health monitoring devices, such as insulin pumps, wearables and more. This can reduce the […]
CamDiab introduces fully closed-loop automated insulin delivery tech
CamDiab announced today that it is introducing CamAPS Liberty, a fully closed-loop feature for its CamAPS FX app. The integration of Liberty — which the company labeled the world’s first fully closed-loop feature — supports users with type 1 diabetes when daily demands prove challenging. It pauses the need to count carbohydrates or deliver meal […]
Trinity Biotech expects pivotal trial for CGM+ in 2026, platform moves toward regulatory submissions
Trinity Biotech (Nasdaq:TRIB) today provided an update on the expected timeline for its CGM+ continuous glucose monitoring (CGM) system. Dublin, Ireland-based Trinity unveiled the CGM+ next-gen wearable biosensor in July 2025. With CGM+, the company aims to take on the growing AI wearables market. The company said it has the system in the later stages […]
MiniMed completes $538M IPO, retains $309M in proceeds as Medtronic separation takes shape
MiniMed (Nasdaq:MMED) announced today that it completed its previously announced initial public offering (IPO). Shares of MMED began trading on Friday, March 6, following the pricing of the IPO that day. They closed today, March 9, down 2.7% at $18 apiece. The Medtronic Diabetes unit priced its IPO at $20 per share, offering 28 million […]
Analysts outline future catalysts for Dexcom with 15-Day CGM, potential reimbursement wins
BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company’s senior investor relations (IR) officials. Marie Thibault, Sam Eiber and Alexandra Pang of BTIG hosted Dexcom Senior VP, IR and Finance, Sean Christiensen, IR Manager Joseph Deltorchio and Director, IR, Matthew Carey for virtual meetings last week. They said the meetings […]
Sequel fully launches twiist automated insulin pump in US, looks to expand access for type 1 diabetes
Sequel Med Tech today announced the broad availability of its twiist automated insulin delivery system in the U.S. The company plans to expand access to automated insulin delivery for people with type 1 diabetes through a wider rollout of the pump, making it fully available nationwide. Manchester, New Hampshire–based Sequel built its twiist system to […]
MiniMed expects to close $644M IPO next week ahead of Medtronic split
MiniMed has set the price for its planned initial public offering (IPO) ahead of an imminent separation from Medtronic (NYSE:MDT). The Medtronic Diabetes unit’s IPO includes 28 million shares of common stock priced at $20 apiece, amounting to $560 million. Underwriters also have an option to purchase up to 4.2 million additional shares at the […]
